Journal of Clinical Endocrinology & Metabolism, Vol 81, 4476-4478, Copyright © 1996 by Endocrine Society

ARTICLES

Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population

RM Cuddihy and RS Bahn
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

Although an association between the human leukocyte antigen (HLA) allele DR3 and Graves' disease (GD) is well documented, the potential role of non-HLA-linked alleles in susceptibility to GD is an area of active investigation. In an attempt to study the potential role of two non-HLA susceptibility alleles in GD and Graves' ophthalmopathy, we examined 286 North American Caucasian individuals (145 normal controls and 141 individuals with GD) for the presence of the A2 allele of the interleukin-1 (IL-1) receptor antagonist gene. In addition, we examined a subset of this population (83 normal controls and 89 individuals with GD) for a specific polymorphism within exon 5 of the IL-1 alpha gene. We found the A2 allelic frequencies (0.25 and 0.23, respectively) and carriage rates (43% and 41%, respectively) in the two groups to be nearly identical. However, findings in the subgroup of patients with the extrathyroidal manifestations of GD (Graves' ophthalmopathy, pretibial dermopathy, and acropachy) suggested a trend toward a higher prevalence of the A2 allele in patients with more severe disease. The allelic frequency (0.28) and carriage rate (47%) of the IL-1 alpha exon 5 polymorphism in individuals with GD were nearly identical to those of the control population (0.28% and 45%, respectively). In summary, we were unable to demonstrate an association between these alleles and GD in our study population. We conclude that neither the A2 allele of the IL-1 receptor antagonist gene nor the IL-1 alpha exon 5 polymorphism confers increased susceptibility to GD.

This article has been cited by other articles:

				B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]

				Y. Tomer and T. F. Davies Searching for the Autoimmune Thyroid Disease Susceptibility Genes: From Gene Mapping to Gene Function Endocr. Rev., October 1, 2003; 24(5): 694 - 717. [Abstract] [Full Text] [PDF]

				H. H. Kacem, A. Rebai, N. Kaffel, S. Masmoudi, M. Abid, and H. Ayadi PDS Is a New Susceptibility Gene to Autoimmune Thyroid Diseases: Association and Linkage Study J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2274 - 2280. [Abstract] [Full Text] [PDF]

				Y. Jin, W. Teng, S. Ben, X. Xiong, J. Zhang, S. Xu, Y. Y. Shugart, L. Jin, J. Chen, and W. Huang Genome-Wide Scan of Graves' Disease: Evidence for Linkage on Chromosome 5q31 in Chinese Han Pedigrees J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1798 - 1803. [Abstract] [Full Text] [PDF]

				B. Vaidya, P. Kendall-Taylor, and S. H. S. Pearce The Genetics of Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5385 - 5397. [Full Text] [PDF]

				M. Imgrund, K. Warnatz, M. Uhl, F. Feuerhake, and H. Peter EMO syndrome as a late explanation for pretibial swelling Rheumatology, March 1, 2001; 40(3): 357 - 358. [Full Text] [PDF]

				P. J. Hunt, S. E. Marshall, A. P. Weetman, J. I. Bell, J. A. H. Wass, and K. I. Welsh Cytokine Gene Polymorphisms in Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1984 - 1988. [Abstract] [Full Text]

				Mapping the Major Susceptibility Loci for Familial Graves' and Hashimoto's Diseases: Evidence for Genetic Heterogeneity and Gene Interactions J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4656 - 4664. [Abstract] [Full Text]

				B. Vaidya, H. Imrie, P. Perros, E. T. Young, W. F. Kelly, D. Carr, D. M. Large, A. D. Toft, M. I. McCarthy, P. Kendall-Taylor, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus Hum. Mol. Genet., July 1, 1999; 8(7): 1195 - 1199. [Abstract] [Full Text] [PDF]